Publications of Antoine BOUQUEGNEAU
Bookmark and Share    
Full Text
See detailSerological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2.
Firket, Louis ULiege; Descy, Julie ULiege; Seidel, Laurence ULiege et al

in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2021), 21(11), 3806-3807

Grupper et al. have reported on a positive humoral response post full vaccination with mRNA SARS-CoV2 BNT162b2 in only 51/136 (37.5%) kidney transplant recipients (KTRs) without prior exposure to the ... [more ▼]

Grupper et al. have reported on a positive humoral response post full vaccination with mRNA SARS-CoV2 BNT162b2 in only 51/136 (37.5%) kidney transplant recipients (KTRs) without prior exposure to the virus(1) . We have conducted an IRB-approved (B707201215598-2021/80) prospective small sample-size study comparing the humoral response to BNT162b2 in 40 consecutive individuals early exposed to the Belgian vaccination program, including 20 KTRs with (n=10, COVID-19(+)) versus without (n=10, COVID-19(-)) history of exposure to SARS-CoV-2 and 20 controls including 10 COVID-19(+) versus 10 COVID-19(-). [less ▲]

Detailed reference viewed: 56 (7 ULiège)
Full Text
See detailAge-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.
Nakanishi, Tomoko; Pigazzini, Sara; Degenhardt, Frauke et al

in Journal of Clinical Investigation (2021), Online ahead of print.

BACKGROUND: There is considerable variability in COVID-19 outcomes amongst younger adults-and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the ... [more ▼]

BACKGROUND: There is considerable variability in COVID-19 outcomes amongst younger adults-and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium. METHOD: The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors. FINDINGS: We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2-1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3-1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors. INTERPRETATION: The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality-and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management. FUNDING: Funding was obtained by each of the participating cohorts individually. [less ▲]

Detailed reference viewed: 301 (13 ULiège)
Full Text
See detailProteinuria in COVID‑19: prevalence, characterization and prognostic role
HUART, Justine ULiege; BOUQUEGNEAU, Antoine ULiege; Lutteri, Laurence ULiege et al

in Journal of Nephrology (2021), 34(3), 355-364

Abstract Background Proteinuria has been commonly reported in patients with COVID-19. However, only dipstick tests have been frequently used thus far. Here, the quantifcation and characterization of ... [more ▼]

Abstract Background Proteinuria has been commonly reported in patients with COVID-19. However, only dipstick tests have been frequently used thus far. Here, the quantifcation and characterization of proteinuria were investigated and their association with mortality was assessed. Methods This retrospective, observational, single center study included 153 patients, hospitalized with COVID-19 between March 28th and April 30th, 2020, in whom total proteinuria and urinary α1-microglobulin (a marker of tubular injury) were measured. Association with mortality was evaluated, with a follow-up until May 7th, 2020. Results According to the Kidney Disease Improving Global Outcomes staging, 14% (n=21) of the patients had category 1 proteinuria (<150 mg/g of urine creatinine), 42% (n=64) had category 2 (between 150 and 500 mg/g) and 44% (n=68) had category 3 proteinuria (over 500 mg/g). Urine α1-microglobulin concentration was higher than 15 mg/g in 89% of patients. After a median follow-up of 27 [14;30] days, the mortality rate reached 18%. Total proteinuria and urinary α1-microglobulin were associated with mortality in unadjusted and adjusted models. This association was stronger in subgroups of patients with normal renal function and without a urinary catheter. Conclusions Proteinuria is frequent in patients with COVID-19. Its characterization suggests a tubular origin, with increased urinary α1-microglobulin. Tubular proteinuria was associated with mortality in COVID-19 in our restropective, observational study. [less ▲]

Detailed reference viewed: 77 (12 ULiège)
Full Text
See detailLong-term effects of COVID-19 on kidney function
DELANAYE, Pierre ULiege; HUART, Justine ULiege; BOUQUEGNEAU, Antoine ULiege et al

in Lancet (2021), 397(10287), 1807

Detailed reference viewed: 33 (1 ULiège)
Full Text
See detail[(18)F]FDG PET/CT imaging disproves renal allograft acute rejection in kidney transplant recipients with acute kidney dysfunction: a validation cohort.
LOVINFOSSE, Pierre ULiege; Weekers, Frédéric ULiege; Pottel, Hans ULiege et al

in European journal of nuclear medicine and molecular imaging (2021)

PURPOSE: [(18)F]FDG PET/CT may predict the absence of acute allograft rejection (AR) in kidney transplant recipients (KTRs) with acute kidney injury (AKI). Still, the proposed threshold of 1.6 of the mean ... [more ▼]

PURPOSE: [(18)F]FDG PET/CT may predict the absence of acute allograft rejection (AR) in kidney transplant recipients (KTRs) with acute kidney injury (AKI). Still, the proposed threshold of 1.6 of the mean of mean standardized uptake values (mSUVmean) in the renal parenchyma needs validation. METHODS: We prospectively performed 86 [(18)F]FDG PET/CT in 79 adult KTRs who underwent per-cause transplant biopsy for suspected AR. Biopsy-proven polyoma BK nephropathies (n = 7) were excluded. PET/CT was performed 192 ± 18 min after administration of 254.4 ± 30.4 MBq of [(18)F]FDG. The SUV(mean) was measured in both upper and lower poles of the renal allograft. One-way analysis of variance (ANOVA) and Tukey's studentized range test were sequentially performed. The receiver operating characteristic (ROC) curve was drawn to discriminate "AR" from non-pathological ("normal" + "borderline") conditions. RESULTS: The median age of the cohort was 55 [43; 63] years, with M/F gender ratio of 47/39. The mean eGFR was 31.9 ± 14.6 ml/min/1.73m(2). Biopsies were categorized in 4 groups: "normal" (n = 54), "borderline" (n = 9), "AR" (n = 14), or "others" (n = 2). The median [min; max] mSUV(mean) reached 1.72 [1.02; 2.07], 1.97 [1.55; 2.11], 2.13 [1.65, 3.12], and 1.84 [1.57; 2.12] in "normal," "borderline," "AR," and "others" groups, respectively. ANOVA demonstrated a significant difference of mSUV(mean) among groups (F = 13.25, p < 0.0001). The ROC area under the curve was 0.86. Test sensitivity and specificity corresponding to the threshold value of 1.6 were 100% and 30%, respectively. CONCLUSION: [(18)F]FDG PET/CT may help noninvasively prevent inessential transplant biopsies in KTR with AKI. [less ▲]

Detailed reference viewed: 52 (7 ULiège)
Full Text
See detailAtteintes rénales de la COVID-19
ERPICUM, Pauline ULiege; GROSCH, Stéphanie ULiege; BOUQUEGNEAU, Antoine ULiege et al

in Revue Médicale de Liège. Supplément (2020), 75(supplément 1), 109-114

The SARS-CoV-2 virus causes a respiratory distress syndrome, the main symptom of COVID-19 (for “COronaVIrus Disease 2019”). This infectious disease has been causing a major health and socio-economic ... [more ▼]

The SARS-CoV-2 virus causes a respiratory distress syndrome, the main symptom of COVID-19 (for “COronaVIrus Disease 2019”). This infectious disease has been causing a major health and socio-economic pandemic since December 2019. The pulmonary alveolus is regarded as the main target of SARS-CoV-2. However, this coronavirus is capable of directly or indirectly affecting other organs, including the kidneys. Here, we summarize the presumed pathophysiology of COVID-19 renal disease. The incidence of acute kidney injury ranges from 0,5 to 22 % of all patients infected with SARS-CoV-2. The need for renal replacement therapy is reported in 5-9 % of patients in intensive care. Histological analysis of renal biopsies mainly shows acute tubular necrosis of varying severity, as well as the congestion of glomerular and peri-tubular capillaries. Endothelitis has been described in few cases. Evidence for a factual inflammation of the glomerulus remains controversial. The medium/long term consequences of COVID-19 nephropathy are unknown and will deserve a tight follow-up. [less ▲]

Detailed reference viewed: 469 (19 ULiège)
Full Text
See detailSclerostin within the chronic kidney disease spectrum
BOUQUEGNEAU, Antoine ULiege; Evenepoel, Peter; PAQUOT, Francois ULiege et al

in Clinica Chimica Acta (2019), 502

Detailed reference viewed: 59 (1 ULiège)
Full Text
See detailLa néphropathie lupique : les nouvelles perspectives de traitement
JADOT, Virginie ULiege; Krzesinski, Jean-Marie ULiege; VON FRENCKELL, Christian ULiege et al

in Néphrologie et Thérapeutique (2017), 14

Systemic lupus erythematosus is a chronic autoimmune disease. Both acquired and innate immune systems are involved in the development of this systemic disease. Lupus nephritis usually is the most serious ... [more ▼]

Systemic lupus erythematosus is a chronic autoimmune disease. Both acquired and innate immune systems are involved in the development of this systemic disease. Lupus nephritis usually is the most serious manifestation of systemic lupus erythematosus, with significant morbidity and mortality. The physiopathological development of the renal involvement of lupus has been increasingly elucidated over the years and various target therapies have recently been developed. After some physiopathological reminders, we discuss the conventional treatment of lupus nephritis as well as the various therapeutic advances, in particular the contribution and the place of the new target therapies in the treatment of the lupus nephritis. [less ▲]

Detailed reference viewed: 233 (4 ULiège)
Full Text
See detailBone disease after kidney transplantation
BOUQUEGNEAU, Antoine ULiege; Salam, Syrazah; DELANAYE, Pierre ULiege et al

in Clinical Journal of the American Society of Nephrology (2016), 11(7), 1282-1296

Detailed reference viewed: 68 (9 ULiège)
Full Text
See detailCreatinine-based equations for the adjustment of drug dosage in an obese population.
BOUQUEGNEAU, Antoine ULiege; Vidal-Petiot, E; Moranne, O et al

in British Journal of Clinical Pharmacology (2016), 81(2), 349-361

Detailed reference viewed: 57 (18 ULiège)
Full Text
See detailAccuracy of Cockcroft&Gault and CKD-EPI equations to estimate glomerular filtration rate in obese population
BOUQUEGNEAU, Antoine ULiege; Vidal-Petiot, E; Vrtovsnik, F et al

Poster (2014)

Detailed reference viewed: 12 (2 ULiège)
Full Text
See detailCockcroft&Gault and CKD-EPI equations: are these equations concordant to adjust drug dosage?
BOUQUEGNEAU, Antoine ULiege; Vidal-Petito, E; Vrtovsnik, F et al

Poster (2014)

Detailed reference viewed: 18 (3 ULiège)
Full Text
See detailMDRD VERSUS CKD-EPI EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN OBESE PATIENTS
BOUQUEGNEAU, Antoine ULiege; CAVALIER, Etienne ULiege; Krzesinski, Jean-Marie ULiege et al

Poster (2013, April 18)

Introduction and Aims: Obesity is recognized as a risk factor both for the development and progression of chronic kidney disease (CKD). Estimating glomerular filtration rate (GFR) is thus especially ... [more ▼]

Introduction and Aims: Obesity is recognized as a risk factor both for the development and progression of chronic kidney disease (CKD). Estimating glomerular filtration rate (GFR) is thus especially important to follow these patients. We have tested the performances of two creatinine-based equations, namely the MDRD and CKD-EPI equations, in an obese population. Conclusions :Both in the global and subgroup analyses, the CKD-EPI equation did not outperform the MDRD study equation. The performances of both equations were worse in CKD patients. These two conclusions were still valid if indexed GFR was considered. [less ▲]

Detailed reference viewed: 35 (2 ULiège)
Full Text
See detailMalabsorption des hormones thyroïdiennes... ou simple manque de compliance ?
Benoit, Arnaud ULiege; BOUQUEGNEAU, Antoine ULiege; PETROSSIANS, Patrick ULiege et al

in Revue Médicale de Liège (2013), 68(3), 118-121

Detailed reference viewed: 200 (9 ULiège)
Full Text
See detailEstimation du débit de filtration glomérulaire chez l’obèse : MDRD ou CKD-EPI ?
Vidal-Petiot, E; DELANAYE, Pierre ULiege; BOUQUEGNEAU, Antoine ULiege et al

Poster (2013)

Detailed reference viewed: 51 (3 ULiège)
Full Text
See detailLe médicament du mois : Fébuxostat (Adenuric®)
DELANAYE, Pierre ULiege; BOUQUEGNEAU, Antoine ULiege; DUBOIS, Bernard ULiege et al

in Revue Médicale de Liège (2012), 67(4), 202-209

Detailed reference viewed: 132 (2 ULiège)
Full Text
See detailLa néphropathie tubulo-interstitielle aiguë: une cause rare d’insuffisance rénale aiguë
BOUQUEGNEAU, Antoine ULiege; Longton, J.; Bovy, Christophe ULiege et al

in Revue Médicale de Liège (2010), 65(7-8), 459-463

We report the case of an acute renal failure due to an acute interstitial nephropathy (ATIN) induced by non steroidal anti-inflammatory drugs (NSAID). Even though this pathology is a rare cause of acute ... [more ▼]

We report the case of an acute renal failure due to an acute interstitial nephropathy (ATIN) induced by non steroidal anti-inflammatory drugs (NSAID). Even though this pathology is a rare cause of acute renal failure, it still requires special attention in view of the fact that it induces a high risk of acute morbidity but it also can evolve into chronic renal failure. Its differential diagnosis with other causes of acute renal failure becomes essential because of the different therapeutic care. In this article, we are going to briefly sum up the reasoning to adopt in order to diagnose an acute renal failure. [less ▲]

Detailed reference viewed: 193 (19 ULiège)